Basilea Pharmaceutica AG (BSLN) - Total Liabilities
Based on the latest financial reports, Basilea Pharmaceutica AG (BSLN) has total liabilities worth CHF145.69 Million CHF as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Basilea Pharmaceutica AG - Total Liabilities Trend (2002–2024)
This chart illustrates how Basilea Pharmaceutica AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Basilea Pharmaceutica AG Competitors by Total Liabilities
The table below lists competitors of Basilea Pharmaceutica AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Autobacs Seven Co.Ltd
F:AB6
|
Germany | €92.86 Billion |
|
Naphtha
TA:NFTA
|
Israel | ILA3.16 Billion |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
USA | $1.59 Billion |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
China | CN¥681.04 Million |
|
Beijing Career International Co Ltd
SHE:300662
|
China | CN¥1.99 Billion |
|
BLACK DIAMOND GRP LTD
F:8B8
|
Germany | €620.93 Million |
|
CeriBell, Inc
NASDAQ:CBLL
|
USA | $40.47 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Basilea Pharmaceutica AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.73 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Basilea Pharmaceutica AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Basilea Pharmaceutica AG (2002–2024)
The table below shows the annual total liabilities of Basilea Pharmaceutica AG from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CHF176.76 Million | -3.56% |
| 2023-12-31 | CHF183.29 Million | -24.12% |
| 2022-12-31 | CHF241.56 Million | -21.03% |
| 2021-12-31 | CHF305.87 Million | -7.82% |
| 2020-12-31 | CHF331.84 Million | +5.54% |
| 2019-12-31 | CHF314.43 Million | -9.76% |
| 2018-12-31 | CHF348.44 Million | -11.25% |
| 2017-12-31 | CHF392.61 Million | +8.23% |
| 2016-12-31 | CHF362.76 Million | -5.50% |
| 2015-12-31 | CHF383.88 Million | +92.47% |
| 2014-12-31 | CHF199.45 Million | -12.86% |
| 2013-12-31 | CHF228.88 Million | -15.18% |
| 2012-12-31 | CHF269.84 Million | +221.93% |
| 2011-12-31 | CHF83.82 Million | -21.15% |
| 2010-12-31 | CHF106.30 Million | -2.37% |
| 2009-12-31 | CHF108.88 Million | -15.19% |
| 2008-12-31 | CHF128.38 Million | +1.61% |
| 2007-12-31 | CHF126.34 Million | +39.18% |
| 2006-12-31 | CHF90.78 Million | +3.52% |
| 2005-12-31 | CHF87.69 Million | +314.02% |
| 2004-12-31 | CHF21.18 Million | +26.60% |
| 2003-12-31 | CHF16.73 Million | -33.43% |
| 2002-12-31 | CHF25.13 Million | -- |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more